Skip header and navigation

1 records – page 1 of 1.

Prevalence and management of severe asthma in primary care: an observational cohort study in Sweden (PACEHR).
Respir Res. 2018 01 18; 19(1):12
Publication Type
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Kjell Larsson
Björn Ställberg
Karin Lisspers
Gunilla Telg
Gunnar Johansson
Marcus Thuresson
Christer Janson
Author Affiliation
Work Environment Toxicology, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Respir Res. 2018 01 18; 19(1):12
Publication Type
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Aged, 80 and over
Anti-Asthmatic Agents - therapeutic use
Asthma - diagnosis - epidemiology - therapy
Cohort Studies
Disease Management
Middle Aged
Primary Health Care - methods
Severity of Illness Index
Sweden - epidemiology
Severe and uncontrolled asthma is associated with increased risk of exacerbations and death. A substantial proportion of asthma patients have poor asthma control, and a concurrent COPD diagnosis often increases disease burden. The objective of the study was to describe the prevalence and managemant of severe asthma in a Swedish asthma popuöation.
In this observational cohort study, primary care medical records data (2006-2013) from 36 primary health care centers were linked to data from national mandatory Swedish health registries. The studied population (>18 years) had a record of drug collection for obstructive pulmonary disease (ATC code R03) during 2011-2012, and a physician diagnosed asthma (ICD-10 code J45-J46) prior to drug collection. Severe asthma was classified as collection of high dose inhaled steroid (> 800 budesonide or equivalent per day) and leukotriene receptor antagonist and/or long-acting beta-agonist. Poor asthma control was defined as either collection of =600 doses of short-acting beta-agonists, and/or =1 exacerbation(s) during the year post index date.
A total of 18,724 asthma patients (mean 49 years, 62.8% women) were included, of whom 17,934 (95.8%) had mild to moderate and 790 (4.2%) had severe asthma. Exacerbations were more prevalent in severe asthma (2.59 [2.41-2.79], Relative Risk [95% confidence interval]; p?
Cites: Am J Respir Crit Care Med. 2011 Mar 1;183(5):589-95 PMID 20889908
Cites: Allergy. 2013 Dec;68(12):1520-31 PMID 24410781
Cites: J Allergy Clin Immunol Pract. 2014 Nov-Dec;2(6):759-67 PMID 25439368
Cites: Eur Respir J. 2014 Feb;43(2):343-73 PMID 24337046
Cites: Cochrane Database Syst Rev. 2014 Mar 10;(3):CD010115 PMID 24615270
Cites: Eur Respir J. 2000 Nov;16(5):802-7 PMID 11153575
Cites: J Allergy Clin Immunol. 2015 Apr;135(4):896-902 PMID 25441637
Cites: J Allergy Clin Immunol. 2007 Jun;119(6):1337-48 PMID 17416409
Cites: Clin Exp Allergy. 2012 May;42(5):706-11 PMID 22515391
Cites: PLoS One. 2011 Feb 17;6(2):e16082 PMID 21379386
Cites: Ann Am Thorac Soc. 2014 Oct;11(8):1210-7 PMID 25166217
Cites: J Allergy Clin Immunol. 2006 Oct;118(4):899-904 PMID 17030244
Cites: Int J Chron Obstruct Pulmon Dis. 2016 Jun 16;11:1297-306 PMID 27366057
Cites: Thorax. 2013 Nov;68(11):1029-36 PMID 24130228
Cites: BMC Pulm Med. 2006 Jun 13;6:13 PMID 16772035
Cites: Chest. 2013 Dec;144(6):1788-1794 PMID 23990003
Cites: J Asthma. 2012 Mar;49(2):144-52 PMID 22277052
Cites: Thorax. 2011 Oct;66(10):910-7 PMID 21106547
Cites: BMJ. 2013 May 29;346:f3306 PMID 23719639
Cites: Respir Med. 2013 Oct;107(10):1481-90 PMID 23643487
Cites: Allergy Asthma Proc. 2010 Jan-Feb;31(1):60-7 PMID 20167146
Cites: J Med Econ. 2013;16(3):342-8 PMID 23216016
Cites: Ups J Med Sci. 2012 Mar;117(1):52-6 PMID 22335391
Cites: Thorax. 2015 Jul;70(7):683-91 PMID 25948695
Cites: Allergy. 2011 May;66(5):671-8 PMID 21255035
PubMed ID
29347939 View in PubMed
Less detail